What research presented at San Antonio Breast Cancer Symposium is most likely to change practice?
BELLE-2 trial: PIK3CA status in circulating tumor DNA predicts efficacy of buparlisib plus fulvestrant in postmenopausal women with endocrine-resistant hormone receptor-positive HER-2–negative advanced breast cancer.
Complication and economic burden of local therapy options for early breast cancer.
GeparSixto trial: Early survival analysis of the addition of carboplatin to neoadjuvant therapy for triple-negative and HER-2–positive early breast cancer.
IBIS-II DCIS study: Anastrozole vs. tamoxifen for the prevention of loco-regional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ.
TH3RESA study: Ado-trastuzumab emtansine improves OS vs. treatment of physician's choice in patients with previously treated HER-2–positive metastatic breast cancer.
Other.
Submit
View Results
See this poll on:
https://poll.fm/9267327/embed